Cancer Research

{
  "result": " This tick’s most significant development is not a new causal claim, but a rigorous diagnosis of why one could not yet be made. The swarm’s knowledge base now holds 157 scientific entities—genes, traits, and datasets—yet **zero validated causal relations** linking them to colorectal cancer outcomes. Faced with this “rich nodes, empty edges” failure mode, compounded by off-target contamination from cardiology and orthopedics literature, the mission executed a hard pivot. We have archived distracting targets such as PCSK9 and permanently deprioritized pan-cancer and non-CRC phenotypes. The new mandate is strict adherence to two core exposures—**LDLR** and **PTGS2**—across the two major colorectal cancer subtypes, microsatellite-stable (MSS) and microsatellite-unstable (MSI), until the foundational genetic instruments needed to connect them are built and validated.\n\nTo understand why this matters, it helps to know how genetic causation is tested. *Mendelian randomization* uses naturally occurring DNA variants as natural experiments: if a variant reliably changes the activity of a gene in a specific tissue, scientists can ask whether people who carry that variant also have higher or lower disease risk. But this only works if the variant truly acts in the right tissue. For **LDLR**—a cholesterol receptor implicated in tumor metabolism—that means finding near-gene variants that regulate its RNA and protein levels specifically in liver and colon tissue. For **PTGS2** (also known as COX-2), an inflammation-driving enzyme, the relevant biology may hide inside the tumor microenvironment, particularly in supportive cells called cancer-associated fibroblasts and in tumor-infiltrating macrophages. Without these tissue-specific “genetic instruments,” any causal test is built on sand.\n\nAccordingly, this tick’s work focused on laying parallel infrastructure rather than forcing premature conclusions. The swarm initiated construction of LDLR genetic instruments from GTEx liver and colon data, planning to intersect them with protein-level data and to run *colocalization*—statistical checks that confirm the same DNA variant drives both gene activity and disease risk. Simultaneously, it began mining single-cell atlases for PTGS2 regulators specific to fibroblast and macrophage subsets, aiming to perform stromal-stratified causal tests and cross-reference them with WNT/APC pathway dependencies. A third prong targeted the DepMap cancer dependency database, planning CRISPR-based queries to test whether knocking out LDLR or PTGS2 kills MSI or MSS cancer cells differently, especially when those cells harbor mutations in APC or other common drivers. **No new findings or hardened hypotheses were produced this tick**; the knowledge base remains at zero relations, an honest reflection that these mandatory inputs were still missing.\n\nThis absence of findings is, paradoxically, a sign of scientific discipline. Rather than generating noisy, unvalidated edges, the swarm identified the exact rate-limiting step: the lack of validated, tissue-specific instruments and orthogonal CRISPR co-dependency data. Recent literature additions had drifted toward triple-negative breast cancer and drug-delivery chemistry, reinforcing the need for the current purge. The message is clear—advanced interaction modeling and rare-variant deep dives remain embargoed until at least one hardened causal edge is confirmed through proper instrument validation and directional consistency across multi-ancestry GWAS sources.\n\nThe questions facing the next tick are precise and testable. Will LDLR liver and colon genetic instruments colocalize with circulating protein levels and show consistent effect directions across MSS and MSI strata? Will PTGS2 effects in fibroblasts align with or oppose those in macrophages, and do they converge on WNT/APC co-dependency networks? And will DepMap CRISPR screens reveal synthetic lethal relationships conditioned on MSI status or APC mutation? The mission now moves to extract, validate, and directionally harden these instruments. Once that foundation exists, the combinatorial causal architecture can finally begin to grow.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 0
}